World-leading dementia scientists talk about the controversies surrounding new Alzheimer’s drugs.
Dementia impacts 55 million folks worldwide, and its commonest kind, Alzheimer’s, accounts for about 70 % of all instances.
On the Alzheimer’s Affiliation Worldwide Convention, the most important congress advocating dementia science, held in Amsterdam this month, a pharmaceutical firm disclosed particulars of its trials of a brand new drug: donanemab.
The American firm, Eli Lilly, expects the US Meals and Drug Administration (FDA) to determine by the tip of 2023 whether or not to approve what it’s calling a “breakthrough” drug.
However is that this medicine the easiest way ahead? Or does it simply provide money circulation for the pharmaceutical trade?
Main dementia scientists Edo Richard and Craig Ritchie discuss to Al Jazeera.